Algert Global LLC Cuts Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Algert Global LLC has reduced its stake in Vaxcyte, Inc. by 23.1%, holding 56,179 shares worth approximately $2.12 million as of the latest SEC filing.
• Other institutional investors increased their positions in Vaxcyte significantly, with Parallel Advisors LLC raising its investment by 203.6% and IFP Advisors Inc by 376.4% during the first quarter.
• Vaxcyte's stock currently holds a consensus rating of Buy from analysts, with an average price target of $136.50, despite the company posting a quarterly EPS loss of ($1.22).

Algert Global LLC decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,179 shares of the company's stock after selling 16,890 shares during the quarter. Algert Global LLC's holdings in Vaxcyte were worth $2,121,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Vaxcyte by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 12,043,805 shares of the company's stock valued at $454,774,000 after acquiring an additional 82,118 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in shares of Vaxcyte by 57.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock worth $116,469,000 after buying an additional 518,255 shares in the last quarter. Invesco Ltd. grew its position in Vaxcyte by 7.7% in the 1st quarter. Invesco Ltd. now owns 1,255,827 shares of the company's stock valued at $47,420,000 after purchasing an additional 89,773 shares during the period. Deutsche Bank AG boosted its stake in shares of Vaxcyte by 5.6% in the 4th quarter. Deutsche Bank AG now owns 1,212,706 shares of the company's stock worth $99,272,000 after buying an additional 64,522 shares during the last quarter. Finally, Northern Trust Corp increased its position in Vaxcyte by 11.9% in the fourth quarter. Northern Trust Corp now owns 1,160,001 shares of the company's stock worth $94,958,000 after buying an additional 123,584 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Trading Down 0.9%

Shares of NASDAQ:PCVX traded down $0.27 during mid-day trading on Wednesday, reaching $29.98. The stock had a trading volume of 388,717 shares, compared to its average volume of 1,762,460. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06. The business's 50 day moving average price is $33.49 and its 200 day moving average price is $43.61. The company has a market cap of $3.89 billion, a P/E ratio of -7.30 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the prior year, the company posted ($1.10) EPS. Analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company's stock. According to MarketBeat, Vaxcyte has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.